Status:
RECRUITING
TAVR for Aortic Valve Disease
Lead Sponsor:
Nanjing First Hospital, Nanjing Medical University
Conditions:
Aortic Valve Disease
Eligibility:
All Genders
18+ years
Brief Summary
Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surg...
Eligibility Criteria
Inclusion
- Clinical diagnosis of severe aortic stenosis or aortic regurgitation
- Patients undergo transcatheter aortic valve replacement
Exclusion
- patients refuse the clinical follow-up
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2037
Estimated Enrollment :
5000 Patients enrolled
Trial Details
Trial ID
NCT05439863
Start Date
July 1 2022
End Date
December 30 2037
Last Update
November 15 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nanjing First Hospital
Nanjing, Jiangsu, China, 210006